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Metronomic chemotherapy with cytotoxic agents has been shown to inhibit angiogenesis and, conse-
quently, tumor growth by targeting vascular endothelial cells (ECs). In these regimens, anti-tumor
activities additional to anti-angiogenesis may operate. Moreover, chemotherapy typically generates
reactive oxygen species in targeted ECs, which can aﬀect angiogenesis. The aim of the present study
was to assess the systemic eﬀect of low-dosage metronomic treatment with either irinotecan or mito-
xantrone on angiogenesis induced by VEGF-A. Angiogenesis was induced in normal adult rat mesen-
tery by intraperitoneal injection of a low dosage of VEGF-A. Thereafter, irinotecan and mitoxantrone
were infused separately continuously at minimally toxic dosages for 14 consecutive days via a subcuta-
neous osmotic minipump. Angiogenesis was assessed in terms of objective and quantitative variables
using morphologic and computerized image analyses. Irinotecan or mitoxantrone signiﬁcantly stimu-
lated angiogenesis, with ironotecan increasing angiogenesis by 104%, when compared with the vehicle-
treated animals. Low-dosage metronomic chemotherapy with irinotecan or mitoxantrone stimulates
angiogenesis in the normal mesentery of rats, probably by inducing low-level oxidative stress in the tar-
geted ECs. Whether or not this pertains to tumor angiogenesis may be diﬃcult to conﬁrm, as several
anti-tumor modes may operate during low-dosage metronomic chemotherapy.
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In 2000, Browder and colleagues (1) reported
that frequent systemic administration or contin-
uous infusion with cyclophosphamide at a mini-
mally toxic dose inhibited basic ﬁbroblast
growth factor (bFGF)-mediated angiogenesis in
the mouse corneal micropocket assay, induced
the apoptosis of vascular endothelial cells (ECs)
in tumor microvessels, and suppressed the
growth of transplantable mouse tumors. In the
same year, Klement and coworkers (2) reported
on the following eﬀects of frequent intraperito-
neal (i.p.) injections of low dosages of vinblastine
in mice: (i) no signiﬁcant eﬀect on body-weight;
(ii) signiﬁcantly reduced vascularity of subcuta-
neous (s.c.) Matrigel pellets that contained
bFGF; (iii) signiﬁcant albeit transient xenograft
tumor regression; (iv) diminished tumor vascu-
larity; and (v) direct inhibition of tumor Received 7 February 2011. Accepted 30 August 2011
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147angiogenesis in SCID mice. The presumptive
target cell in these studies was the normal angio-
genically activated EC, and continuous chemo-
therapy-induced apoptosis of ECs in the
vascular bed of tumors has been shown to pre-
cede the apoptosis of nearby neoplastic cells (3).
As tumor progression is angiogenesis-depen-
dent, the beneﬁt of this continuous scheduling is
that it is signiﬁcantly less toxic and has more
potent anti-tumor eﬀects than conventional,
spaced-out, high-dosage chemotherapy, owing
in large part to the fact that extended periods of
treatment become feasible (4). An additional
advantage of continuous chemotherapy is that
the targeted ECs are rapidly exposed to the cir-
culating drugs, and as ECs are considerably
more stable genetically than neoplastic cells,
they are less prone to mutate and acquire drug
resistance. In addition to its eﬀects on ECs and
pericytes, metronomic chemotherapy aﬀects
neoplastic tumor cells, tumor stroma cells
(including ﬁbroblasts, macrophages, and mast
cells), platelets, lymphocytes, as well as precur-
sor ECs in the bone marrow, which may signiﬁ-
cantly inﬂuence tumor angiogenesis and growth.
The success of continuous chemotherapy
scheduling in tumor-bearing mice, in which the
tumor cells were cyclophosphamide-resistant,
led to this treatment being labeled anti-angio-
genic chemotherapy (1). Continuous treatment
scheduling is now more generally referred to as
metronomic chemotherapy. Metronomic che-
motherapy has been used in a multitude of pre-
clinical studies (5–8), as well as in clinical trials
(9–15). In many of these studies, the combina-
tion of metronomic chemotherapy and conven-
tional anti-angiogenic agents was tested, which
often enhanced the anti-tumor eﬀect while mak-
ing it diﬃcult to evaluate the eﬃcacy of the pur-
ported anti-angiogenic eﬀect per se in the
tumors of continuous chemotherapy.
Recently, the mechanism by which cytotoxic
chemotherapy aﬀects the tumor vasculature was
thought to include selective killing of ECs, sup-
pression of circulating EC precursor cells
and⁄or increasing levels of endogenous angio-
genesis inhibitors, and decreasing levels of
angiogenesis stimulators (16). In 2006, using the
rat mesentery angiogenesis model, which diﬀers
in many important aspects from the corneal
micropocket and the s.c. Matrigel pellet assays
used by Browder et al. (1) and Klement et al.
(2), respectively, as discussed elsewhere (17, 18),
we reported that continuous low-dosage infu-
sions of chemotherapeutics inﬂuenced VEGF-A
(VEGF)-mediated angiogenesis in a drug-spe-
ciﬁc manner (19). In this model, cyclophospha-
mide [conﬁrming the data of Browder et al. (1)],
as well as vinblasine [conﬁrming the data of
Klement et al. (2)], and paclitaxel signiﬁcantly
suppressed angiogenesis, whereas cisplatin and
5-ﬂuorouracil, paradoxically, signiﬁcantly stim-
ulated angiogenesis (19). Notably, neither doxo-
rubicin nor epirubicin displayed signiﬁcant
eﬀects (19, 20).
In the present investigation, we assessed the
eﬀect of continuous s.c. infusion of either irino-
tecan or mitoxantrone on angiogenesis induced
by VEGF, which is a major pro-angiogenic fac-
tor in most experimental and human tumors.
The tumor-free rat mesentery angiogenesis assay
was used, and angiogenesis was measured in





Adult young outbred male Sprague-Dawley rats
(B&K Universal, Sollentuna, Sweden) were acclima-
tized to a standardized environment for at least
7 days, fed ad libitum and randomly allocated to
weight-matched groups with two animals housed per
cage (21). At the start of the pro-angiogenic i.p. treat-
ment with VEGF, the mean body weights were
232.1 g and 179.3 g in the irinotecan and mitoxan-
trone experiments, respectively. Body weight was
monitored daily. Given the rapid physiologic growth
of adult rats (gaining approximately 60 g per week)
drug-related, weight-gain retardation is a sensitive
surrogate marker of toxicity, systemic well-being,
anorexia, and failure to thrive. The Animal Ethics
Committee of the University of Gothenburg
approved this study. The ethical guidelines were those
established by Workman et al. (22).
Angiogenesis induction and a note on the mesentery
assay
Rat rVEGF164 (564-RV⁄CF; R&D Systems Europe
Ltd., Oxon, UK), which is the predominant VEGF
isoform in rats, was diluted to 96 pmole⁄mL in the
endotoxin-free saline used for infusion into patients,
frozen and thawed and a volume of 5 mL was injected
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given twice daily for 4.5 days, i.e., from Monday
morning (Day 0) to Friday morning (Day 4) induces
a robust sprouting angiogenesis response in the mes-
enteric test tissue, peaking at around Day 21 (23).
Subsequent to the i.p. VEGF treatment, s.c. infusion
with irinotecan or mitoxantrone was administered for
14 consecutive days. The VEGF treatment did not
aﬀect body-weight-gain, as compared with controls
treated i.p. with the saline vehicle.
In similarity to most normal adult tissues, the mem-
branous, small-gut mesentery in rats is natively vascu-
larized (albeit sparsely), and signiﬁcant physiologic
angiogenesis is lacking in adult Sprague-Dawley rats
(17). The test tissue is untouched mechanically until
the experiment is concluded. The inﬂammatory stim-
ulus of the test tissue is minimal, which ensures a high
level of sensitivity, as inﬂammation induces angiogen-
esis. The assay replicates the clinical circumstances, as
the test drugs are administered systemically and the
observed outcome reﬂects the net eﬀect of all the met-
abolic, cellular, and molecular changes induced by
the treatment.
Continuous subcutaneous infusion of irinotecan or
mitoxantrone for 14 days
Filling and implanting of osmotic minipumps – On
Day 5, i.e., 1 day after the end of the i.p. VEGF treat-
ment, osmotic minipumps (Model 2ML2, with con-
stant pumping rate of 5.0 lL⁄h for 14–15 days;
Alzet
  Osmotic Pumps, Mountain View, CA, USA)
were ﬁlled under sterile conditions with the irinotecan
or mitoxantrone solution or the appropriate vehicle.
After storage in sterile 0.9% (w⁄v) NaCl overnight at
37  C, the pumps were surgically implanted s.c. on
the backs of rats that had been anesthetized with
inhaled isoﬂurane (Forene
 ; Abbott, Abbott Park,
IL, USA). The skin incision made for pump implanta-
tion was sutured immediately post-implantation using
silk thread. As the animals gained weight physiologi-
cally during the experimental period, the actual dos-
age of drug per kg of body weight was higher than the
average dosage at the beginning of the infusion period
and below the average dosage at the end of the infu-
sion period. Continuous infusion, as used in the pres-
ent study, can be viewed as an extended form of
metronomic treatment.
Irinotecan (Campto
 ; Pﬁzer, New York, NY,
USA), which was placed in a tube that was wrapped
in aluminum foil after dilution, was administered at
50 mg⁄kg⁄wk in the vehicle, which consisted of NaCl
0.9% (w⁄v), sorbitol 0.45% (w⁄v), and lactic acid
0.09% (w⁄v) (pH 3.5). Rats that received vehicle
alone (controls) were included in each experiment.
Mitoxantrone (Novantrone
 ; Pﬁzer) was adminis-
tered at 0.5 mg⁄kg⁄wk in the vehicle, which consisted
of NaCl 0.8% (w⁄v), Na-acetate 0.005% (w⁄v), and
aceticacid0.046%(w⁄v)(pH3.0–4.5),withorwithout
N-acetylcysteine (NAC; Sigma Chemical Co., St.
Louis,MO,USA) at192 mg⁄kg⁄day.NAC,whichis a
potent anti-oxidant, has been widely used as a tool for
investigating the roles of reactive oxygen species
(ROS) in biologic and pathologic processes. NAC was
administered to two of the four groups of animals
(Table 2) without aﬀecting body-weight gain (data not
shown).Ratsthatreceivedvehiclealoneorvehicleplus
NAC(controls)wereincludedineachexperiment.
The dosage of a drug per body surface area
(mg⁄m
2) may be useful for comparing drug toxicities
between species, e.g., between laboratory animals and
humans (24). For a rat that weighs 250 g, the dosage
in mg⁄kg multiplied by seven yields the approximate
dosage in mg⁄m
2. Thus, the dosages used for each
250-g animal in the angiogenesis experiment corre-
spond to 350 mg⁄m
2 per week for irinotecan and
3.5 mg⁄m
2 per week for mitoxantrone in a human.
Angiogenesis quantiﬁcation
After 14 days of continuous drug infusion, four mem-
branous, virtually transparent (window-like) samples
from the most distal part of the small-gut mesentery
directly proximal to the ileo-cecal valve, were col-
lected and examined microscopically after being
spread intact on objective slides and stained immuno-
histochemically (23). Normally, this tissue has a
thickness of only 5–10 lm in its avascular parts, mak-
ing the whole microvessel network virtually two-
dimensional. The surrounding fatty tissue distinctly
delineates each window. The entire vasculature of
each of the four mesenteric windows per animal was
visualized using a primary monoclonal antibody
against rat endothelium, MRC OX-43 (19), which
labels the vascular endothelium in all tissues of the
rat, except that of the brain capillaries. This proce-
dure allows the reliable identiﬁcation of even the
smallest microvessels.
For the analysis of objective unbiased microvessel
variables, microscopic morphometry and computer-
ized image analysis were employed in a blinded fash-
ion. First, the total area of each sampled mesenteric
windows was measured. The following variables were
then measured in each window (23): (i) the percentage
vascularized area (VA), which is a measurement of
the spatial extension of the network; and (ii) the
microvascular length (MVL), which is a composite
measurement of microvessel density. The total micro-
vascular length (TMVL) was calculated according to
the following formula: TMVL = VA · the mean
MVL per treatment group.
Statistical analysis
The non-parametric Mann–Whitney U-test was
used to analyze unpaired (two-tailed) observations.
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used as the independent data-point for each variable
of the mesenteric window. The criterion for statistical
signiﬁcance was p £ 0.05.
RESULTS
Eﬀect of 14-day continuous irinotecan or mitoxantrone
infusion on angiogenesis
The animals behaved normally in both experi-
ments. The doses used did not produce signs of
toxicity (see below). Chemotherapy did not
aﬀect the area (size) of the individual sampled
mesenteric windows, as compared with those of
the vehicle controls (data not shown). There-
fore, direct comparisons with the vehicle con-
trols can be made for all the angiogenesis
variables presented.
Irinotecan infusion increased the value for VA
(to 168% of the value for the vehicle control;
p £ 0.05), MVL (to 121% of the value for the
vehicle control; p > 0.05), and TMVL (204% of
the vehiclecontrol; p £ 0.005)(Table 1).
At sacriﬁce, the mean body weight ofthe irino-
tecan-treated animals was 1% lower than that
of the vehicle controls (381.2 ± 8.2 g, mean ±
SEM), which during the 14 days of s.c. infusion
treatment showed a mean increase in weight of
60.6 g⁄week (the diﬀerence in mean body weight
at any time-point during the s.c. infusion was
£1% between the treatment groups).
Mitoxantrone infusion without NAC signiﬁ-
cantly increased the TMVL, as compared with
the appropriate vehicle control (to 169% of the
TMVL for the vehicle control; p £ 0.03)
(Table 2). In animals that were not exposed to
mitoxantrone, infusion of the vehicle plus NAC
led to increases in the VA (141% of the vehicle
control; p > 0.05), MVL (144% of the vehicle
control; p > 0.05), and TMVL (203% of the
vehicle control; p £ 0.025) (Table 2).
At sacriﬁce, the mean body weight of the mito-
xantrone-treatedanimalswas1%lowerthanthat
of the vehicle controls (339.1 ± 6.6 g, mean ±
SEM) (see Group 1 in Table 2), which over the
14 days of s.c. infusion showed a mean increase
in weight of 62.1 g⁄week (the diﬀerence in mean
body weight among the four treatment groups at
anytime-pointduringthes.c.infusionwas£2%).
DISCUSSION
Important aspects of the assay used
As the inhibition of angiogenesis limits tumor
growth and vice versa (4, 25), it can be argued
that a study of the angiogenesis-modulating
eﬀects per se of any potential anti-tumor drug
should be conducted in a tumor-free tissue.
VEGF is a key angiogenic factor in tumor
development and appears to be a mediator of
angiogenic pathways that involve a number of
other pro-angiogenic factors. As discussed
below, the rat mesentery used in the present
study appears to be a satisfactory surrogate
model for tumor angiogenesis, in part because
the ECs involved in tumor angiogenesis use the
same signaling pathways as the ECs that are
involved in non-tumor angiogenesis (26).
The assay used compares well with other
mammalian in vivo angiogenesis assays in regard
particularly to important features such as the
adulttest tissue is natively vascularized andlacks
signiﬁcant physiologic angiogenesis; minimal
trauma, if any, is inﬂicted upon the tissue; truly
quantitative variables are measured, which
allows sound statistical analysis regarding
dose-response and molecular-activity studies;
sprouting angiogenesis occurs, which is the
predominant form in tumors; toxic data are
Table 1. Eﬀects of 14 days of subcutaneous infusion
of irinotecan (50 mg⁄kg⁄week) on VEGF-mediated





VA 13.71 ± 2.00 23.06 ± 4.77
1
100 168
MVL 0.89 ± 0.09 1.08 ± 0.08
100 121
TMVL 12.20 ± 1.44 24.90 ± 3.74
2
100 204
Vehicle used: NaCl 0.9% w⁄v, sorbitol 0.45% w⁄v,
lactic acid 0.09% w⁄v (pH 3.5).
MVL, microvascular length, a composite measure of
microvessel density; TMVL, total microvascular
length (VA x MVL); VA, vascularized area, a mea-
sure of microvessel spatial extension.
1p £ 0.05,
2p £ 0.005 compared with the vehicle con-
trol. There were 14 animals in each group. Data
shown as mean ± SEM.
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logically in adulthood; the assay is highly suited
to studies of the combined eﬀects on angiogene-
sis of agents that are administered systemically
in a concurrent or sequential fashion; and the
assay replicates the clinical situation, as the
angiogenesis-modulating test drugs are adminis-
tered systemically and the responses observed
reﬂect the net eﬀect of all the metabolic, cellular,
and molecular alterations induced by the treat-
ment. The assay is discussed in invited review
articles in terms such as of biological relevance,
ethical aspects, economy and labor intensity (17,
18), and is demonstrated in a video presentation
with attached detailed protocol (27). However,
this assay does not take into account all aspects
of tumor-induced angiogenesis, e.g., the pres-
ence of multiple pro-angiogenic factors, which
are usually present in advanced cancers, the cha-
otic microvessel patterns and perfusion of the
tumor vasculature, the cellular composition of
the perivascular stroma, and the heterogeneity
of the ECs within individual tumors. Signiﬁcant
diﬀerences in pO2 and pH are also noted
between tumorous and non-tumorous tissues.
Nevertheless, in a rat model of syngeneic pros-
tate cancer, the present assay for VEGF-medi-
ated angiogenesis revealed a close correlation
between the anti-angiogenic eﬀects in the tumor-
free mesentery and the anti-tumor eﬀects result-
ing from continuous s.c. infusion of paclitaxel
(28). Moreover, mouse ascites tumor cells induce
a repertoire of biologic responses in the mesen-
tery vasculature, which can be attributed entirely
to VEGF (29). Additional conﬁrmation that
inhibition of VEGF-induced angiogenesis in the
tumor-free mesentery reﬂects signiﬁcant events
leading to the inhibition of tumor growth
comes from the fact that systemic treatment
with bovine iron-unsaturated lactoferrin
suppresses VEGF-induced angiogenesis in the
rat mesentery model (30), as well as cancer cell-
induced angiogenesis in a mouse dorsal air sac
assay (31).
How to study anti-angiogenesis in tumors?
The alleged target of low-dosage metronomic
chemotherapy is the angiogenically activated
normal ECs. Whether or not the ECs in tumors
and in normal tissues are genetically and func-
tionally identical remains controversial (32),
even though the tumor endothelium exhibits a
phenotype of angiogenically activated ECs in
normal tissue, as reﬂected in the high levels of
expression of angiogenic molecules, such as
VEGFR, the angiopoietin receptor Tie2, and
the adhesive molecules ICAM-1, E-selectin, and
CD44 (26). It is noteworthy that tumor angio-
genesis is not a well-deﬁned concept, as in
tumors, there is a constant cross-talk between
the genetically heterogeneous neoplastic cells,
the ECs, stromal cells (including ﬁbroblasts),
leukocytes (including lymphocytes), sentinel
immune cells (mast cells, macrophages and
dendritic cells), platelets, and the extracellular
matrix. Mainly due to the dynamic genetic het-
erogeneity among the neoplastic cells, angiogen-
esis-related features may be tumor-speciﬁc in
principle. It should also be remembered that
there may be substantial diﬀerences in angio-
genesis between authochthonous tumors
Table 2. Eﬀects of 14 days of subcutaneous infusion of mitoxantrone (0.5 mg⁄kg⁄week) on VEGF-mediated
angiogenesis
Group 1 Group 2 Group 3 Group 4
Vehicle without
NAC n = 10
Vehicle with
NAC n = 8
Mitoxantrone without
NAC n = 12
Mitoxantrone with
NAC n = 12
% of corresponding value for Group 1
VA 14.98 ± 2.13 21.08 ± 4.64 19.07 ± 2.98 16.97 ± 3.93
100 141 127 113
MVL 0.79 ± 0.12 1.14 ± 0.14 1.05 ± 0.09 0.94 ± 0.07
100 144 133 119
TMVL 11.83 ± 1.68 24.03 ± 5.29
1 20.02 ± 3.13
2 15.95 ± 3.69
100 203 169 135
Vehicle used: NaCl 0.8% w⁄v, Na-acetate 0.005% w⁄v, acetic acid 0.046% w⁄v (pH 3.0–4.5). NAC, N-acetylcys-
teine.
1p £ 0.025;
2p £ 0.03 compared with Group 1. Data are shown as mean ± SEM.
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the main tumor type seen in the clinic, and
transplanted tumors (also including xenograft
tumors) (33). Moreover, many of the tumor
models used in pre-clinical studies are clearly
dissimilar in important respects to most human
tumors. There are also distinct diﬀerences
between inbred mouse strains in terms of
responsiveness to growth factor-stimulated
angiogenesis (34). These factors make compari-
sons between studies using diﬀerent tumor mod-
els diﬃcult. From the clinical perspective of
anti-angiogenic therapy, it would appear that
the predictive value for translation into the
clinic of data obtained in a number of trans-
planted tumor models is limited.
Divergent angiogenesis-modulating eﬀects of irinotecan
and mitoxantrone
We report that low-dosage continuous infusion
of either irinotecan or mitoxantrone enhances
VEGF-induced angiogenesis in the normal rat
mesentery. This is in contrast with previous
reports of both mitoxantrone and irinotecan
having anti-angiogenic activities in a variety of
in vivo and in vitro models. Mitoxantrone, for
example, has been reported to suppress angio-
genesis in the tumor-free surgical rat cornea
pocket and in the embryonic chick chorioallan-
toic membrane assays in vivo (35, 36). Irinotecan
has been found to inhibit angiogenesis in several
in vivo tumor xenograft models in mice (6, 32,
37–39), and in EC cultures (6, 40). In some of
these studies, low-dosage irinotecan treatment
inhibited hypoxia-inducible factor (HIF)-1
alpha and⁄or up-regulated the anti-angiogenic
protein thrombospondin-1. We speculate that
the current conﬂicting data hinge on the fact
that the rat mesentery assay encompasses a
unique set of features among in vivo angiogene-
sis models (such as an adult natively vascular-
ized visceral tumor-free tissue that is inﬂuenced
minimally by inﬂammation and not exposed to
either surgery⁄trauma or high levels of oxygen).
Furthermore, the assay allows objective, unbi-
ased variables to be assessed quantitatively. The
rat mesentery model compares favorably with
most of the assays used in the cited articles (17,
18). However, the relevance of the various pre-
clinical assays to human pathobiology remains
to be established.
There are numerous discrepancies in the liter-
ature concerning the angiogenesis-modulating
eﬀects of various standard cytotoxic agents in
tumors and tumor-free assays (19, 41, 42). This
is not surprising considering the diﬀerences in
species used, experimental design, test tissues
used, modes of administration, dosages, and the
biological features of the assays (17). In many of
these models used for the study of the eﬀects of
chemotherapeutics on angiogenesis, trauma is
induced, which aﬀects the test tissue. This is a
problem because cell injury generates ROS,
which fragment the extracellular matrix compo-
nent hyaluronan, which in turn synergizes with
ROS to activate the innate immune system and
further promote ROS production and angiogen-
esis (43). Assays in which the new blood vessels
are close to tissue-air interfaces may, moreover,
allow exposure to artiﬁcially high concentra-
tions of oxygen, with consequential ROS pro-
duction, as in the corneal micropocket and
chick embryonic chorioallantoic membrane
assays (17). Major models of angiogenesis occa-
sionally yield dissimilar, and in some cases even
contradictory outcomes (18).
Reactive oxygen species, anti-oxidants, chemotherapy
and angiogenesis in vivo
Transcription factors and genes involved in
angiogenesis are regulated by ROS and the sig-
naling properties of ROS are due, in part, to
reversible oxidative inactivation of redox-sensi-
tive target proteins, such as nuclear factor
kappa B (NF-kB) (44, 45). Normally, there is a
balance between the production and removal of
ROS. An imbalance in favor of the pro-oxida-
tive state is often referred to as ‘oxidative stress’.
In tumors, ROS, such as superoxide anion and
hydrogen peroxide (H2O2), are found in large
quantities (46). The drugs of many classes of
chemotherapeutics generate in a dose-depen-
dent manner a high level of oxidative stress in
biological systems (47). Importantly, ROS
appear to have biphasic eﬀects on angiogenesis,
in that high levels induce cell death, apoptosis,
and senescence of ECs, while low levels function
as intracellular signaling molecules in ECs.
These ROS-dependent intracellular signaling
molecules play an important role both in physio-
logic as well as pathologic angiogenesis by medi-
ating cell growth, migration, and diﬀerentiation,
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genesis (44, 48). In fact, H2O2 potently induces
VEGF expression in wounds; this oxidant-
induced VEGF expression is independent of
HIF-1 alpha (49). Low levels of H2O2 also play
a role in the angiogenic switch (48) and are
essential for the trophic eﬀects of a wide variety
of cytokines (50).
Studying the eﬀects of chemotherapy on
angiogenesis is complex because (i) VEGF stim-
ulation per se increases ROS production via the
activation of Rac1-dependent NADPH-oxidase
in ECs (44). Moreover, ROS are important for
the activation of VEGF-induced cSrc (a master
cellular control protein that is involved in cell
proliferation, diﬀerentiation, motility, angio-
genesis, and other functions) activation, phos-
phorylation of VE-cadherin, and protein kinase
B⁄Akt in ECs, thereby additionally stimulating
angiogenesis (44). ROS at low levels generated
by H2O2 under normoxia induce HIF-1 alpha
transcription via binding of NF-kB (45); (ii)
ROS are able to instigate angiogenesis (44, 48).
As demonstrated in the present study, NAC sig-
niﬁcantly enhanced VEGF-mediated angiogene-
sis in animals that were not exposed to
mitoxantrone (Table 2), which suggests that
redox-related eﬀects that aﬀect VEGF-induced
angiogenesis operate in this model. Although
the mechanism underlying this apparently
pro-angiogenic eﬀect of NAC remains to be
elucidated, it may be related to reducing the
oxidative stress induced by VEGF to a more
optimal angiogenesis-stimulating level.
Reactive oxygen species, anti-oxidants, and angiogene-
sis in vitro
Studies of ROS-associated processes in cultured
ECs are not uncomplicated given that: (i) cell
culturing inﬂuences antigen expression in human
ECs, which means that the phenotype changes
early in response to culture conditions (51); (ii)
the media used to grow ECs contain growth fac-
tors, i.e., stimulatory agents that may inﬂuence
the cell phenotype (51); (iii) oxidative stress
occurs in all cell cultures; in particular, riboﬂa-
vin, which is a necessary component of cell cul-
ture media, is responsible for the generation of
ROS (52); and (iv) there are major diﬀerences in
characteristics of ECs derived from diﬀerent tis-
sues, making comparisons between experiments
diﬃcult (53, 54). Considering the intricate rela-
tionships between the production of ROS by
chemotherapeutics, the spontaneous production
of ROS in cell cultures and the phenotypic modi-
ﬁcation and diversity of cultured ECs, the data
obtained from in vitro experiments on the alleged
direct eﬀects of chemotherapeutics on ECs
(often referred to as ‘in vitro angiogenesis’)
should probably be interpreted with caution.
Metronomic chemotherapy exerts diverse anti-tumor
eﬀects
Several potentially independent modes of anti-
angiogenic⁄anti-tumor eﬀects may operate indi-
vidually or in combination during low-dosage
continuous chemotherapy. These eﬀects include:
(i) angiogenesis modulation via direct eﬀects of
the cytotoxic agent on the vascular ECs, circu-
lating ECs, and EC precursors in the bone mar-
row; (ii) direct eﬀects of the cytotoxic agent on
neoplastic and tumor stromal cells, with conse-
quent inﬂuence on tumor angiogenesis; (iii)
eﬀects on platelets, which play an important role
in angiogenesis in that they accumulate angio-
genesis-regulating proteins in two sets of alpha-
granules, with positive regulators in one set and
negative regulators in the other set (55); these
regulators can be released separately, depending
on the type of therapeutic molecule used; (iv)
selective depletion of speciﬁc immune eﬀector
cells with the potential to evoke tumor immu-
nity (56); (v) eﬀects on the redox-state, which
may be crucial for the outcome of angiogenesis
modulation following low-dosage treatment
with certain cytotoxic agents (19); and (vi) the
induction of the potent endogenous anti-angio-
genic proteins endostatin and thrombospondin
in ECs and possibly in other cells (16, 57, 58).
Clearly, analyses of normal tissues and
tumors are needed to clarify the relative contri-
butions of these modes and their respective
eﬀects on the anti-tumor outcome of continuous
chemotherapy. Elucidation of the inﬂuences of
these diverse anti-tumor modes would facilitate
the design of eﬀective therapeutic strategies.
CONCLUSIONS
In the literature, it is often stated that metro-
nomic chemotherapy has anti-angiogenic
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  2011 The Authors APMIS   2011 APMIS 153eﬀects. Investigating the eﬀects of chemothera-
peutics on angiogenesis per se is, however, com-
plicated because: (i) in addition to aﬀecting
cellular metabolism, cytotoxic agents can
up-regulate and down-regulate genes and gener-
ate ROS in targeted ECs (the production of
ROS is dose-dependent and possibly tissue-
dependent); and (ii) in vitro, spontaneous gener-
ation of ROS in cells grown in culture media
has an impact on the results. The eﬀect on
VEGF-mediated angiogenesis of metronomic
mono-chemotherapy in the rat mesentery model
is drug-speciﬁc (and dose-related). Thus, previ-
ous studies have reported that these agents are
pro-angiogenic, e.g., ironotecan and, mitoxan-
trone (as reported here), as well as cisplatin and
5-ﬂuorouracil (19, 42), anti-angiogenic, e.g.,
cyclophosphamide, paclitaxel, and vinblastine
(19, 41), or have no eﬀect on angiogenesis, e.g.,
doxorubicin and epirubicin (19, 20). Low-level
oxidative stress in ECs appears to induce pro-
angiogenic eﬀects following certain types of
low-dosage metronomic chemotherapy in this
model. Whether or not these ﬁndings hold true
for tumor angiogenesis remains to be clariﬁed.
The present data suggest that when low-
dosage, metronomic, single-drug chemotherapy
with irinotecan or mitoxantrone produces an
anti-tumor outcome one has to take into
account that several separate modes of anti-
tumor eﬀects, including those unrelated to
angiogenesis modulation, may operate in paral-
lel.
ABBREVIATIONS:
bFGF: basic ﬁbroblast growth factor, FGF-2;
EC: vascular endothelial cell; HIF:hypoxia-
inducible factor; i.p.:intraperitoneal; MVL:micr
ovascular length; NAC:N-acetylcysteine; NF-
kB:Nuclear factor kappa; ROS:reactive oxygen
species; s.c.:subcutaneous; TMVL:total micro-
vascular length; VA:vascularized area; VEGF:
vascular endothelial growth factor-A, isoforms
164 and 165.
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